Bloomage Biotechnology Financials
| 688363 Stock | 57.50 3.32 5.46% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 730.2 M | 737.7 M |
|
|
Bloomage | Select Account or Indicator |
Understanding current and past Bloomage Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bloomage Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Bloomage Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of Bloomage Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bloomage Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bloomage Biotechnology's management manipulating its earnings.
Bloomage Biotechnology Stock Summary
Bloomage Biotechnology competes with Saurer Intelligent, Jinhe Biotechnology, Guangzhou KingTeller, Jinling Hotel, and BTG Hotels. Bloomage Biotechnology is entity of China. It is traded as Stock on SHG exchange.Specialization | Basic Materials, Specialty Chemicals |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100003NL9 |
| Business Address | Tech Development Zone, |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.bloomagebioactive.com |
| Phone | 86 531 8268 5998 |
You should never invest in Bloomage Biotechnology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bloomage Stock, because this is throwing your money away. Analyzing the key information contained in Bloomage Biotechnology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bloomage Biotechnology Key Financial Ratios
Bloomage Biotechnology's financial ratios allow both analysts and investors to convert raw data from Bloomage Biotechnology's financial statements into concise, actionable information that can be used to evaluate the performance of Bloomage Biotechnology over time and compare it to other companies across industries.| Revenue | 6.08 B | ||||
| Gross Profit | 6.36 B | ||||
| EBITDA | 664.83 M | ||||
| Net Income | 592.56 M | ||||
| Total Asset | 8.47 B |
Bloomage Biotechnology Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Liab | 62.2M | 56.4M | 145.9M | 186.8M | 214.8M | 225.6M | |
| Net Tangible Assets | 4.1B | 4.5B | 5.2B | 5.8B | 6.6B | 3.4B | |
| Retained Earnings | 620.0M | 1.1B | 1.7B | 2.2B | 2.5B | 1.4B | |
| Other Assets | 30.8M | 69.5M | 276.0M | 279.4M | 321.3M | 337.4M | |
| Total Assets | 5.0B | 5.7B | 7.5B | 8.7B | 8.5B | 5.6B | |
| Other Current Liab | 108.1M | 173.1M | 366.8M | 7.8M | 5.8M | 5.5M | |
| Accounts Payable | 53.3M | 119.1M | 243.5M | 848.3M | 700.8M | 735.9M | |
| Cash | 2.2B | 1.4B | 1.8B | 1.6B | 1.2B | 1.4B | |
| Net Receivables | 400.9M | 372.4M | 396.6M | 448.4M | 447.4M | 391.6M | |
| Inventory | 314.5M | 476.8M | 709.1M | 1.2B | 1.1B | 586.5M | |
| Other Current Assets | 53.1M | 650.1M | 190.4M | 43.2M | 40.1M | 38.0M | |
| Total Liab | 422.1M | 698.8M | 1.8B | 2.0B | 1.5B | 1.0B | |
| Total Current Assets | 3.8B | 3.7B | 4.0B | 4.0B | 3.1B | 3.0B | |
| Intangible Assets | 385.5M | 426.7M | 467.3M | 475.1M | 497.0M | 353.9M | |
| Good Will | 72.7M | 74.6M | 67.2M | 247.2M | 251.3M | 134.9M | |
| Net Invested Capital | 4.6B | 5.0B | 5.9B | 7.0B | 7.1B | 5.2B | |
| Net Working Capital | 3.4B | 3.1B | 2.6B | 2.4B | 1.9B | 2.4B |
Bloomage Biotechnology Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Bloomage Biotechnology. It measures of how well Bloomage is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Bloomage Biotechnology brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Bloomage had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Bloomage Biotechnology has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | 40M | (40M) | 23.8M | 119.7M | 107.7M | 111.7M | |
| Capital Expenditures | 450.2M | 762.8M | 784.2M | 696.4M | 1.0B | 1.1B | |
| Change To Netincome | (25.3M) | 8.7M | 9.5M | 9.8M | 8.8M | 4.9M | |
| Change To Inventory | (141.7M) | (178.5M) | (218.5M) | (437.8M) | 13.9M | 14.6M | |
| Investments | (800M) | (606.9M) | (100.1M) | (836.2M) | (612.9M) | (582.2M) | |
| Change In Cash | 1.3B | (798.5M) | 195.0M | (341.6M) | (430.2M) | (408.7M) | |
| Depreciation | 60.4M | 70.2M | 153.3M | 213.6M | 264.7M | 277.9M | |
| Net Income | 585.6M | 645.8M | 782.3M | 970.9M | 592.6M | 617.8M | |
| End Period Cash Flow | 2.2B | 1.4B | 1.6B | 1.2B | 813.1M | 1.2B | |
| Free Cash Flow | (85.3M) | (57.7M) | 491.9M | (61.2M) | (330.7M) | (314.1M) | |
| Other Non Cash Items | (2.0M) | 11.6M | 10.3M | 4.1M | 35.9M | 37.7M |
Bloomage Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bloomage Biotechnology's current stock value. Our valuation model uses many indicators to compare Bloomage Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bloomage Biotechnology competition to find correlations between indicators driving Bloomage Biotechnology's intrinsic value. More Info.Bloomage Biotechnology Corp is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bloomage Biotechnology Corp is roughly 1.94 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bloomage Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bloomage Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bloomage Biotechnology Systematic Risk
Bloomage Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bloomage Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Bloomage Biotechnology correlated with the market. If Beta is less than 0 Bloomage Biotechnology generally moves in the opposite direction as compared to the market. If Bloomage Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bloomage Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bloomage Biotechnology is generally in the same direction as the market. If Beta > 1 Bloomage Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Bloomage Biotechnology Corp Other Liab Over Time
Bloomage Biotechnology Thematic Clasifications
Bloomage Biotechnology Corp is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Bloomage Biotechnology November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bloomage Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bloomage Biotechnology Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bloomage Biotechnology Corp based on widely used predictive technical indicators. In general, we focus on analyzing Bloomage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bloomage Biotechnology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 34.68 | |||
| Value At Risk | (4.80) | |||
| Potential Upside | 9.45 |
Complementary Tools for Bloomage Stock analysis
When running Bloomage Biotechnology's price analysis, check to measure Bloomage Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bloomage Biotechnology is operating at the current time. Most of Bloomage Biotechnology's value examination focuses on studying past and present price action to predict the probability of Bloomage Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bloomage Biotechnology's price. Additionally, you may evaluate how the addition of Bloomage Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |